

AMENDMENTS TO THE SPECIFICATION

Please replace the paragraph beginning at page 77, line 14, with the following rewritten paragraph:

Fig. 15 shows the histological changes in a Sprague-Dawley rat with chronic renal failure after Aranesp (EPO) treatment (0.1 [[mg]] μ g of Aranesp per kg) one time per week for a period of 6 weeks, beginning immediately after induction of chronic renal failure. The chronic renal failure was caused by removal of the right kidney and ligation of the segmental arteries supplying the upper and lower renal poles of the left kidney. The figure shows a normal glomerulus with delicate afferent vessel. No pathological signs were observed in the tubulointerstitium.

Please replace the paragraph bridging pp. 77-78 of the application with the following rewritten paragraph:

Fig. 16 shows the histological changes in a Sprague-Dawley rat with chronic renal failure after Aranesp (EPO) treatment (0.1 [[mg]] μ g of Aranesp per kg) one time per week for a period of 6 weeks, beginning immediately after induction of chronic renal failure. The chronic renal failure was caused by removal of the right kidney and ligation of the segmental arteries supplying the upper and lower renal poles of the left kidney. The figure shows a normal glomerulus with delicate afferent vessel (630X magnification). No pathological signs were observed in the tubulointerstitium.

Please replace the paragraph beginning at p. 78, line 7, with the following rewritten paragraph:

Fig. 17 shows the histological changes in a Sprague-Dawley rat with chronic renal failure after Aranesp (EPO) treatment (0.1 [[mg]] μ g of Aranesp per kg) one time per week for a period of 6 weeks, beginning immediately after induction of chronic renal failure. The chronic renal failure was caused by the removal of the right kidney and ligation of the segmental arteries supplying the upper and lower renal poles of the left kidney. The figure shows a normal glomerulus with delicate afferent vessel. No pathological signs were observed in the tubulointerstitium.

Please replace the paragraph beginning at p. 78, line 18, with the following rewritten paragraph:

Fig. 18 shows the histological changes in a Sprague-Dawley rat with chronic renal failure after Aranesp (EPO) treatment (0.1 [[mg]] μ g of Aranesp per kg) one time per week for a period of 6 weeks, beginning immediately after induction of chronic renal failure. The chronic renal failure was caused by removal of the right kidney and ligation of the segmental arteries supplying the upper and lower renal poles of the left kidney. The figure shows a normal glomerulus with delicate afferent vessel (630X magnification). No pathological signs were observed in the tubulointerstitium.